A SEER-Medicare Analysis of Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agent

被引：0
|
作者：
Stein, Eytan [1 ]
Latremouille-Viau, Dominick [2 ]
Shi, Sherry [2 ]
Guerin, Annie [2 ]
Wu, Eric [3 ]
Bonifacio, Gaetano [4 ]
Cao, Xiting [2 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Anal Grp Inc, Montreal, PQ, Canada
[3] Anal Grp Inc, Boston, MA USA
[4] Novartis Pharmaceut, E Hanover, NJ USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷
关键词：
myelodysplastic syndromes; hypomethylating agents; real-world; MDS;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MDS-112
引用
收藏
页码：S314 / S315
页数：2
相关论文
共 50 条
  • [1] Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis
    Stein, Eytan M.
    Bonifacio, Gaetano
    Latremouille-Viau, Dominick
    Shi, Sherry
    Guerin, Annie
    Wu, Eric Q.
    Sadek, Islam
    Cao, Xiting
    LEUKEMIA & LYMPHOMA, 2021, 62 (06) : 1411 - 1421
  • [2] Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis
    Stein, Eytan M.
    Latremouille-Viau, Dominick
    Joseph, George J.
    Shi, Sherry
    Guerin, Annie
    Wu, Eric Q.
    Bonifacio, Gaetano
    Cao, Xiting
    BLOOD, 2019, 134
  • [3] Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis
    Stein, Eytan M.
    Bonifacio, Gaetano
    Latremouille-Viau, Dominick
    Shi, Sherry
    Guerin, Annie
    Wu, Eric Q.
    Sadek, Islam
    Cao, Xiting
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 234 - 243
  • [4] Healthcare Resource Utilization and Costs in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis
    Stein, Eytan
    Latremouille-Viau, Dominick
    Shi, Sherry
    Guerin, Annie
    Wu, Eric
    Bonifacio, Gaetano
    Cao, Xiting
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S314 - S314
  • [5] HEALTHCARE RESOURCE UTILIZATION AND COSTS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS: A SEER-MEDICARE ANALYSIS
    Stein, E. M.
    Latremouille-Viau, D.
    Shi, S.
    Guerin, A.
    Wu, E.
    Bonifacio, G.
    Cao, X.
    VALUE IN HEALTH, 2020, 23 : S132 - S133
  • [6] Treatment Patterns and Economic Burden Among Elderly Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A SEER-Medicare Analysis
    Brunner, Andrew M.
    Huggar, David
    Copher, Ronda
    Zhou, Zheng-Yi
    Zichlin, Miriam L.
    Anderson, Annika
    Downes, Nathaniel
    McBride, Ali
    BLOOD, 2021, 138
  • [7] A SEER-MEDICARE DATA ANALYSIS OF ELDERLY GLIOBLASTOMA PATIENTS: TREATMENT PATTERNS, OUTCOMES AND COST
    Burton, Eric
    Ugiliweneza, Beatrice
    Woo, Shiao
    Skirboll, Stephen
    Boakye, Maxwell
    NEURO-ONCOLOGY, 2014, 16
  • [8] Myelodysplastic syndromes and the risk of cardiovascular disease in older adults: A SEER-medicare analysis
    Diego Adrianzen Herrera
    Kith Pradhan
    Rose Snyder
    Siddharth Karanth
    Murali Janakiram
    Ioannis Mantzaris
    Ira Braunschweig
    Anjali Budhathoki
    Urvi A. Shah
    Amit K. Verma
    Santosh B. Murthy
    Aditi Shastri
    Leukemia, 2020, 34 : 1689 - 1693
  • [9] Myelodysplastic syndromes and the risk of cardiovascular disease in older adults: A SEER-medicare analysis
    Herrera, Diego Adrianzen
    Pradhan, Kith
    Snyder, Rose
    Karanth, Siddharth
    Janakiram, Murali
    Mantzaris, Ioannis
    Braunschweig, Ira
    Budhathoki, Anjali
    Shah, Urvi A.
    Verma, Amit K.
    Murthy, Santosh B.
    Shastri, Aditi
    LEUKEMIA, 2020, 34 (06) : 1689 - 1693
  • [10] Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis
    Ailawadhi, Sikander
    Parikh, Kejal
    Abouzaid, Safiya
    Zhou, Zhou
    Tang, Wenxi
    Clancy, Zoe
    Cheung, Claudia
    Zhou, Zheng-Yi
    Xie, Jipan
    BLOOD ADVANCES, 2019, 3 (20) : 2986 - 2994
12345